DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and Dov terminated their relationship in December 2006.   :12 
It is a
triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the  racemic mixture of amitifadine (DOV-21,947) and its (–)- enantiomer, DOV-102,677. Its IC values for 50 SERT, NET, and DAT are K i 14 nM, 20 nM, and 78 nM, respectively. 
As of March 2008, Dov had no intention to further develop DOV-216,303 because the patent on the compound had expired.
See also [ edit ]
References [ edit ]
^ McCoy, Michael (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". C&EN.
^ a b "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008. DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
^ "DOV 216303". AdisInsight . Retrieved . 26 February 2017
^ a b Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. (2006). "Preclinical and Clinical Pharmacology of DOV 216,303, a "Triple" Reuptake Inhibitor". CNS Drug Reviews. 12 (2): 123–134. doi: 10.1111/j.1527-3458.2006.00123.x. PMID 16958986.